SLENYTO DIN 02560798
Status: Marketed
Holder: NEURIM PHARMACEUTICALS LTD.
Health Canada record
| Active ingredient(s) | MELATONIN 1 MG |
|---|
| Dosage form | Tablet (Extended-Release) |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | N05CH01 MELATONIN |
|---|
| Original market date | 16-Jul-2026 |
|---|
| Current status date | 16-Jul-2026 |
|---|
| Source | Health Canada DPD |
|---|
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MELATONIN
| DIN | Product | Company | Form | Strength | Status |
|---|
| 00793167 | PRIME-X MELATONIN IMPLANTS | NEO-DYNAMICS | Implant | MELATONIN 2.7 MG | Marketed |
| 02560801 | SLENYTO | NEURIM PHARMACEUTICALS LTD. | Tablet (Extended-Release) | MELATONIN 5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 35971 | 2025-09-08 | New Drug Submission (NDS) | |
International API supply for MELATONIN
2 valid EDQM Certificates of Suitability from 2 holders. 4 active FDA Drug Master Files.
Request a quote for SLENYTO
How to read a Canadian DIN record